What are the clinically significant drug interactions of ranitidine (Zantac) and how should they be monitored and managed?

Ranitidine Drug Interactions: Clinical Management

Ranitidine has several clinically significant drug interactions that require monitoring, primarily through three mechanisms: competition for renal tubular secretion (procainamide), alteration of gastric pH affecting drug absorption (ketoconazole, atazanavir, delavirdine, gefitinib, glipizide, midazolam, triazolam), and weak inhibition of cytochrome P450 enzymes (warfarin). 1

Key Interaction Mechanisms

Ranitidine affects other drugs through:

• Competition for renal organic cation transport (affecting drugs eliminated by this route)
• Gastric pH elevation (altering absorption of pH-dependent drugs)
• Weak CYP450 inhibition (much less than cimetidine) 2, 1

High-Priority Interactions Requiring Action

Warfarin

Monitor prothrombin time/INR closely during concurrent use. Reports document altered prothrombin time with ranitidine coadministration. Due to warfarin's narrow therapeutic index, check INR more frequently when initiating or discontinuing ranitidine. 1

Procainamide

Monitor for procainamide toxicity when ranitidine doses exceed 300 mg/day. High-dose ranitidine (e.g., for Zollinger-Ellison syndrome) reduces renal excretion of procainamide and N-acetylprocainamide, increasing plasma levels through competition for renal tubular secretion. At standard doses (150 mg twice daily), this interaction is unlikely to be clinically relevant. 1

pH-Dependent Absorption Drugs

Drugs with DECREASED absorption (avoid or separate dosing):

• Ketoconazole: Exposure reduced up to 95% when gastric pH maintained ≥6. The interaction magnitude at standard ranitidine doses (150 mg twice daily) is unknown but likely significant. 1
• Atazanavir: Use with caution; absorption impaired by increased gastric pH. Refer to atazanavir label for specific dosing recommendations. 1
• Delavirdine: Chronic H2-antagonist use not recommended; absorption significantly impaired. 1
• Gefitinib: Exposure reduced 44% with ranitidine coadministration. Use with caution and monitor clinical response. 1

Drugs with INCREASED absorption (monitor for enhanced effects):

• Midazolam (oral): Exposure increased up to 65% with ranitidine 150 mg twice daily. Monitor for excessive or prolonged sedation. IV midazolam shows minimal interaction (9% increase). 1
• Triazolam: Exposure increased approximately 30% with ranitidine 150 mg twice daily. Monitor for excessive sedation. 1
• Glipizide: Exposure increased 34% in diabetic patients after single 150 mg ranitidine dose. Monitor blood glucose when initiating or discontinuing ranitidine. 1

Ranitidine vs. Cimetidine: Critical Distinction

Ranitidine has significantly fewer drug interactions than cimetidine because it binds much more weakly to cytochrome P450 enzymes. 2, 3, 4 Studies confirm ranitidine does NOT significantly interact with:

• Propranolol
• Metoprolol (no pharmacodynamic changes despite minor kinetic effects)
• Atenolol
• Nifedipine (at therapeutic doses)
• Lidocaine
• Phenytoin (rare case reports exist but controlled studies show minimal interaction) 4, 5

However, cimetidine inhibits CYP1A2, 2C9, 2C19, 2D6, 2E1, and 3A4, while ranitidine and famotidine interact weakly or not at all with cytochrome P450. Nizatidine has the lowest interaction potential among H2-antagonists. 2

Practical Management Algorithm

When prescribing ranitidine:

1. Review current medications for high-risk interactions (warfarin, procainamide >300 mg/day ranitidine, ketoconazole, HIV antivirals, benzodiazepines, glipizide)

2. For warfarin patients: Check baseline INR, then recheck 3-5 days after starting/stopping ranitidine, then weekly until stable

3. For antifungals/antivirals: Consider alternative acid suppression (famotidine has less pH effect) or separate administration by 2-4 hours when possible

4. For benzodiazepines: Use IV formulations when possible (minimal interaction) or reduce oral benzodiazepine dose by 25-30% initially

5. For diabetes patients on glipizide: Monitor blood glucose more frequently for 1-2 weeks after ranitidine initiation

6. For high-dose ranitidine (>300 mg/day): Monitor procainamide levels if coadministered

Common Pitfalls to Avoid

• Do not assume ranitidine is interaction-free simply because it's safer than cimetidine—several clinically significant interactions exist 1
• Do not overlook gastric pH-dependent interactions—these can be as significant as metabolic interactions
• Do not use chronic ranitidine with delavirdine—this combination is specifically not recommended 1
• Do not forget renal dose adjustment—ranitidine is primarily renally excreted, requiring dose reduction in renal impairment 1

Note: While ranitidine was withdrawn from many markets in 2019-2020 due to NDMA contamination concerns, understanding these interactions remains relevant for clinical practice where it may still be encountered and for understanding H2-antagonist class effects. 6